

Please type a plus sign (+) inside this box → ☐

(Modified) PTO/SB/21 (6-98)
Approved for use through 09/30/2000. OMB 0651-0031
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

TRANSMITTAL FORM

(to be used for all correspondence after initial filing)

Application Number	09/849,592
Filing Date	May 4, 2001
First Named Inventor	Edward T. We
Group Art Unit	1631
Examiner Name	Unassigned
Attorney Docket Number	407T-976201US

Total Number of Pages in This Submission

5

ENCLOSURES (check all that apply)

- ☐ Fee Transmittal Form
 - ☐ Fee Attached
- ☐ Amendment / Response
 - ☐ After Final
 - ☐ Affidavits/declaration(s)
- ☐ Extension of Time Request
- ☐ Express Abandonment Request
- ☒ Information Disclosure Statement
- ☐ Certified Copy of Priority Document(s)
- ☐ Response to Missing Parts/Incomplete Application
- ☐ Response to Missing Parts under 37 CFR 1.52 or 1.53

- ☐ Assignment Papers (for an Application)
- ☐ Drawing(s)
- ☐ Licensing-related Papers
- ☐ Petition Routing Slip (PTO/SB/69) and Accompanying Petition
- ☐ Petition to Convert to a Provisional Application
- ☐ Power of Attorney, Revocation Change of Correspondence Address
- ☐ Terminal Disclaimer
- ☐ Small Entity Statement
- ☐ Request for Refund

- ☐ After Allowance Communication to Group
- ☐ Appeal Communication to Board of Appeals and Interferences
- ☐ Appeal Communication to Group (Appeal Notice, Brief, Reply Brief)
- ☐ Proprietary Information
- ☐ Status Letter
- ☒ Additional Enclosure(s) (please identify below):

receipt acknowledgment postcard

Authorization to Charge Deposit Account

Please charge Deposit Account No. 50-0893 for any additional fees associated with this paper or during the pendency of this application, including any extensions of time for consideration of the documents enclosed.

Remarks

SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT

Firm or Individual name

Jonathan Alan Quine, Reg. No. 41,261 Quine Intellectual Property Law Group P.C.

Signature

Jonathan Alan Quine

Date

January 2, 2003

CERTIFICATE OF MAILING

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Assistant Commissioner for Patents, Washington, D.C. 20231 on this date: January 2, 2003

Typed or printed name

Amelia Groth

Signature

Amelia Groth

Date

January 2, 2003



I hereby certify that this correspondence is
being deposited with the United States
Postal Service as first class mail in an envelope addressed to:

Assistant Commissioner for Patents,
Washington, D.C. 20231,
On January 2, 2003

Quine Intellectual Property Law Group, P.C.

By


Amelia Groth

RECEIVED

JAN 31 2003

TECH CENTER 1600/2900

#4/I.D.S.

Attorney Docket No. 407T-976201US

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

Edward T. Wei, *et al.*

Application No.: 09/849,592

Filed: May 4, 2001

For: MELANOCORTIN RECEPTOR
ANTAGONISTS AND MODULATIONS
OF MELANOCORTIN RECEPTOR
ACTIVITY

Examiner: Unassigned

Art Unit: 1631

INFORMATION DISCLOSURE
STATEMENT UNDER 37 CFR § 1.97 and
§ 1.98

Assistant Commissioner for Patents
Washington, D.C. 20231

Sir:


The references cited on the attached PTO-1449 form are being called to the attention of the Examiner to make of record references cited in parent application USSN 09/031,902 (now U.S. Patent 6,228,840) filed February 27, 1998. Pursuant to 37 CFR § 1.98(d), copies of references cited in parent application USSN 09/031,902 (now U.S. Patent 6,228,840) filed February 27, 1998 are not provided. However the applicants will gladly provide fresh copies of any references requested by the Examiner. It is respectfully requested

that the cited information on the attached 1449 form(s) be expressly considered during the prosecution of this application, and that references be made of record therein and appear among the "references cited" on any patent to issue therefrom.

As provided for by 37 CFR 1.97(g) and (h), no inference should be made that the information and references cited are prior art merely because they are in this statement and no representation is being made that a search has been conducted or that this statement encompasses all the possible relevant information.

Applicant believes that no fee is required for submission of this statement, since it is being submitted prior to the first Office Action. However, if a fee is required, the Commissioner is authorized to deduct such fee from the undersigned's Deposit Account No. 50-0893. Please deduct any additional fees from, or credit any overpayment to, the above-noted Deposit Account.

Respectfully submitted,



Jonathan Alan Quine
Reg. No. 41,261

QUINE INTELLECTUAL PROPERTY LAW GROUP, P.C.
P.O. Box 458
Alameda, CA 94501
Tel: (510) 337-7871
Fax: (510) 337-7877

JAQ:ag

Substitute for form 1449A-B/PTO

INFORMATION DISCLOSURE
STATEMENT BY APPLICANT

Complete if Known

Application Number	09/849,592
Filing Date	May 4, 2001
First Named Inventor	Edward T. W i
Group Art Unit	1631
Examiner Name	Unassigned
Attorney Docket Number	407T-976201US
Date Submitted	January 2, 2003

(use as many sheets as necessary)

U.S. PATENT DOCUMENTS

Examiner Initials	Cite No.	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, lines, Where Relevant Passages or Relevant Figures Appear
		Number	Kind Code (if known)			
	01	4,016,100		Suzuki et al.	04-05-1977	
	02	4,091,090		Sipos	05-23-1978	
	03	4,348,384		Horikoshi et al.	09-07-1982	
	04	5,126,327		Takeuchi	06-1992	
	05	5,480,869		Wei et al.	01-02-1996	
	06	5,482,930		Wei et al.	01-09-1996	
	07	5,514,670		Friedman et al.	05-07-1996	

RECEIVED

JAN 31 2003

TECH CENTER 1600/2900

FOREIGN PATENT DOCUMENTS

Examiner Initials	Cite No.	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T
		Office	Number	Kind Code (if known)				
	08	GB	2193891			08-14-1987		
	09	WO	97/47316			12-18-1997		

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS

Examiner Initials	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T
	12	Dooley et al. (1996) "New, Highly Active Orphanin Receptor Ligands Identified Using Combinatorial Libraries," poster abstract from the 27 th Meeting of the International Narcotics Research Conference, abstract TU13, Long Beach, California, 1996.	
	11	Hadley et al. (1996) "Melanocortin Receptors: Identification and Characterization by Melanotropic Peptide Agonists and Antagonists," <i>Pigment Cell Res.</i> , pp. 213-234.	
	12	Henderson and McKnight (1997) "The Orphan Opioid Receptor and Its Endogenous Ligand - Nociceptin/Orphanin FG," <i>Trends in Pharmacological Sciences</i> , 18, pp. 293-300.	
	13	Ollmann et al. (1997) "Antagonism of Central Melanocortin Receptors in Vitro and in Vivo by Agouti-Related Protein," <i>Science</i> , 278, pp. 135-138.	
	14	Quillan and Sadee (1997) "Dynorphin Peptides: Antagonists of Melanocortin Receptors," <i>Pharmaceutical Research</i> , 14:6, pp. 713-719.	
	15	Siegrist and Eberle (1995) Melanocortins and Their Implication in Melanoma," <i>TEM</i> , 6:4, pp. 115-120.	

Examiner
Signature

Date
Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Substitute for form 1449A-B/PTO

INFORMATION DISCLOSURE
STATEMENT BY APPLICANT

(use as many sheets as necessary)

Complete if Known

Application Number	09/849,592
Filing Date	May 4, 2001
First Named Inventor	Edward T. W i
Group Art Unit	1631
Examiner Name	Unassigned
Attorney Docket Number	407T-976201US
Date Submitted	January 2, 2003

- | | |
|----|--|
| 16 | Siegrist et al. (1997) "Interactions of α -Melanotropin and Agouti on B16 Melanoma Cells: Evidence for Inverse Agonism of Agouti," J. Recept. Signal. Transduct. Res., 17, pp. 75-98. |
| 17 | Berge et al. (1977) "Pharmaceutical Salts," J. Pharm. Sci., 66:1, pp. 1-19. |
| 18 | Yang et al. (1997) "Effects of Recombinant Agouti-Signaling Protein on Melanocortin Action," Mol. Endocrinol., 11, pp. 274-2880. |
| 19 | Sawyer et al. (1989) Peptide Research, 2(1), 140-146. |
| 20 | Thomas et al. (1995) Peptides, 16(3), 547-50. |
| 21 | Vlasov et al. (1996) Proc. Eur. Pept. Symp., 24 th , Meeting Date 1996, 877-878. Editors: Ramage, Robert; Epton, Roger. Publisher: Mayflower Scientific, Kingswinford, UK. |
| 22 | Dowdy et al. (1995) Photodermatol., Photoimmunol. Photomed., 11(4), 143-8 |
| 23 | Zhang et al. (1996) Chin. Med. Sci. J. 11(2)63-68. |

RECEIVED

JAN 31 2003

TECH CENTER 1600/2910

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.